2001～2005年《中国妇幼健康研究》载文被引分析

目的 从文献引证角度透视《中国妇幼健康研究》的论文学术水平、期刊质量和影响力.方法 依据《中国生物医学期刊引文数据库》,利用科学文献计量学方法对《中国妇幼健康研究》载文被《中国生物医学期刊引文数据库》来源期刊引用情况进行统计分析及评价.结果 2001～2005年平均发文被引比例为34.43%,单篇论文平均被引2.11次,单篇论文最高被引为18次.单篇被引4次以上论文42篇,共被引266次,占总被引篇数的14.89%,占被引总频次的41.24%.645篇被引论文中,共有作者274人,作者最高被引篇数为5篇.被引1篇的作者238人,占作者总数的86.86%.有278种期刊引用《中国妇幼健康研究》,自引率为0.028.结论 《中国妇幼健康研究》所载文献质量较高,形成具有独立风格和特色且相对稳定的研究体系.该刊不仅是我国妇幼卫生健康研究领域重要的信息源之一,受到同行较高程度的关注,也是我国医学领域的主要核心期刊.     

2006-2015年全国疑似预防接种异常反应监测数据分析文献描述性分析

目的 通过对全国2006-2015年公开发表的疑似预防接种异常反应(AEFI)监测数据分析文献(简称"AEFI分析文献")进行分析,了解全国AEFI监测工作的开展情况.方法 以中国学术文献网络出版总库中2006-2015年间公开发表的AEFI分析文献为研究对象,整理分析其发表年份、基金论文比、主要发表期刊、核心作者情况、第一作者单位情况、研究对象及研究内容等.结果 最终纳入文献中,2006-2015年间文献发表数量及其定基比发展速度和增长速度总体均呈上升趋势;其中基金论文共27篇,占最终纳入文献的5.73%,2015年基金论文占比最高,为12.96%;共464篇文献刊登于各种期刊上,其中刊登过8篇及以上AEFI分析文献的期刊共20种.本研究核心作者共52人,所有核心作者共发表AEFI分析文献121篇,占最终纳入文献的25.69%.最终纳入文献的第一作者单位所在地分布于30个省市/自治区,其中江苏省最多.最终纳入文献均采用描述性流行病学研究方法进行研究,97.45%的文献对引起AEFI的疫苗种类分布及报告发生率进行了分析,88.96%的文献描述了研究对象的三间分布特征,85.77%的文献对AEFI个案的临床诊断进行了分析,48.83%的文献对AEFI监测报告质量进行了描述分析.结论 2006-2015年间,全国AEFI分析文献发表数量整体呈上升趋势,以期刊论文为主,基金论文比偏低;作者单位以公共卫生机构为主,文献主要来源于经济发达的东部地区及科研实力较强的中部地区.结合目前状况,监测工作者及各级AEFI监测部门要重视AEFI监测工作、继续加强相关培训、定期对监测数据进行分析报告,以加强各部门对监测数据的交流利用.     

2002-2011年《情报资料工作》论文作者分析

目的 探讨《情报资料工作》载文作者、机构、地区分布情况,了解科研人员合作类型及特点,确定核心著者、核心机构和核心地区.方法 用文献计量学方法对该刊2002-2011年论文作者发文量、合作情况、地区分布、系统分布、核心作者、高产单位等进行统计分析.结果 该刊2002-2011年发文1 662篇,发文1篇作者1 014人,占第1作者人数80.67％,作者合作论文585篇,合作率35.20％,合作度1.45,独著论文1 077篇(64.80％),高等院校发文1 386篇(83.39％),科研院所发文140篇(8.42％),省、市图书馆发文46篇(2.77％),核心著者83人,发文328篇(19.74％),高产单位22个,发文618篇(37.18％),北京地区发文252篇(15.16％)居第1位.结论 《情报资料工作》作者分布范围广,合作度较低,高等院校是主要作者群.     

基于文献计量法分析我国医疗保险的研究形势

运用文献计量学方法,对2000-2012年间我国医疗保险研究的相关文献进行统计,并从年代分布、关键词词频、核心作者、期刊来源及基金资助情况等方面进行分析,探讨当前我国医疗保险相关文献的研究形势,希望能够对我国当前医疗保险相关文献的研究方向、层次、特征进行合理的分析和总结,以期为相关部门及人员提供借鉴和参考。     

2000-2002年《卫生研究》载文统计分析

《卫生研究》是中国预防医学科学院主办的公共卫生专业学术期刊 ,双月刊 ,全国公开发行 ,从文献计量角度 ,对其载文及作者进行了统计分析 ,有助于读者对该刊的特点、论文质量、学术水平的了解。1　资料来源与统计指标1 1　资料来源　 2 0 0 0 - 2 0 0 2年出版的 18期《卫生研究》。1 2　统计指标　包括载文量、引用文献、发表时滞、栏目设置、第 1作者地区分布、单位类别与论著数量、论著作者合著情况、第一作者发文量等。1 3　研究方法　文献计量方法2　结果与分析2 1　载文量　 2 0 0 0 - 2 0 0 2年期刊载文 4 90篇 ,总页数为 12 81页。…     

优秀论文评选结果

正《预防医学》2018年第5期刊出论文经编辑部推荐,专家审议,评选出优秀论文5篇,编辑部将向优秀论文作者颁发荣誉证书。优秀论文名单如下:1.刘小畅,赵婷,赵志梅等作者《中国居民病毒性肝炎流行趋势分析》2.沈玮玮,许才明,荣超等作者《失独家庭成员生命质量及影响因素研究》3.张丹丹,洪航,姜海波作者《宁波市男男性行为人群抑郁状况调查》     

2006-2011年《中国科技期刊研究》刊出论文作者分析

目的 探讨《中国科技期刊研究》载文作者、机构、地区分布情况,了解作者合作类型及特点,确定核心著者、核心机构和核心地区.方法 用文献计量学方法对该刊2006-2011年论文作者发文量、合作情况、地区分布、系统分布、核心作者、高产单位等进行统计分析.结果 该刊6年发表论文1 795篇,其中作者合著论文1 027篇,合著率57.21％,合作度2.23;独著论文768篇(42.79％).发表1篇论文的作者819人,占第1作者总人数的70.90％;核心作者59人(5.12％),发表论文347篇(19.33％).高产单位15个,发文288篇(16.04％).北京、江苏和陕西地区的作者发表论文分别为502篇(27.97％)、138篇(7.69％)和133篇(7.41％),位居前3位.结论 该刊作者分布范围广,合作率高,并拥有一支实力雄厚,对刊物影响较大、造诣较深的活跃核心作者群,但核心作者数量及所发表的论文数量还有待提高.     

基于CiteSpace的我国专科护理质量指标研究可视化分析

目的 了解我国专科护理质量指标研究热点及发展趋势,为进一步推动专科护理质量深入研究提供参考。方法 在中国学术期刊全文数据库(CNKI)、万方数据知识服务平台、维普期刊全文数据库检索我国2000年1月1日-2022年9月13日发表于中文核心期刊的专科护理质量指标相关研究。采用CiteSpace 6.1.R3软件对发文量、作者和研究机构合作情况、高频关键词、关键词共现和突现词等进行可视化分析。结果 共纳入149篇文献,发文量总体呈上升趋势。研究机构和作者分布均较分散,相互合作不紧密。研究热点有护理质量、质量指标、德尔菲法、护理管理等,研究前沿为敏感指标和满意度等。结论 我国专科护理质量指标研究处于发展阶段。建议相关机构和研究者持续关注专科护理质量指标研究,拓宽研究视角,规范指标临床实证研究,丰富指标构建方法,关注患者结局指标,加强护理信息化建设等。     

我国2001～2010年临床路径研究文献分析

目的分析临床路径研究现状。方法选用中国生物医学文献数据库(CBM),检索2001～2010年临床路径研究相关文献,采用NoteExpress、Excel、手工处理等,统计分析发文时间、主题分布、作者、作者单位、省市分布、刊发期刊等内容。结果检索到临床路径研究相关文献1 167篇。其中,基金论文185篇,占总发文数的15.85%;文献数量逐年递增;第一作者共974名,只发表1篇论文的第一作者约占第一作者总数的88.40%(861/974);频次最高的前10个主题词为临床路径、健康教育、住院时间、费用及医疗、随机对照试验、病人满意度、护理工作、医院管理、统计学(主题)、质量控制;研究人员和单位主要分布在广东、北京、江苏等地。结论自2001年以来,我国临床路径研究取得了较大进展,但研究认为,需继续深入在临床路径运行机制、质量评估、变异处理等纵向的研究,为进一步高效推广临床路径夯实基础。     

2006-2010年《中国肿瘤》高被引论文分析

目的通过高被引论文分析《中国肿瘤》杂志学术水平和发展方向以及期刊质量。方法对"中国引文数据库"中《中国肿瘤》2006-2010年的被引论文进行统计,运用普赖斯定律确定高被引论文。对高被引论文的被引频次、作者分布、作者合作情况、研究主题等进行分析。结果 2006-2010年《中国肿瘤》被引文献833篇,总被引频次3 222次,篇均被引频次3.9次,单篇最高被引频次达109次。高被引论文85篇,占全部论文数量的10.2%;高被引论文总被引频次1 328次,占所有论文总被引频次的41.2%。高被引论文作者合作度4.8;合作率92.9%。高被引论文作者主要研究方向是肿瘤的预防控制,主要分布在北京、浙江、广东、江苏、上海、福建等地。结论 2006-2010年《中国肿瘤》杂志高被引论文数量不大,但相对占总被引频次较高,作者合作率高,影响较大,在我国的肿瘤防控工作中独具特色,发挥重要作用。     

卫生经济成本效果分析的前沿评价方法研究

健康与卫生保健是卫生领域里最受关注的经济和政治问题。由于卫生经济学涉及公共政策的制定和实施,所以,我们必须系统地评价可供选择的政策方案。通过对国内外相关文献中3种经济评价方法的阐述,着重介绍和分析了成衣效用分析法,并认为该方法在现阶段的中国更具有实际应用价值。     

Systematic review of health economic evaluation studies of dengue vaccines

Objectives

To review the literature on economic evaluation of dengue vaccination to produce evidence to support a local cost-effectiveness study and to subsidize the decision to introduce a dengue vaccine in the Brazilian National Immunization Program. Methods: We systematically searched multiple databases (MEDLINE (via PubMed), EMBASE, SCOPUS, NHS Economic Evaluation Database (NHS EED), HTA Database (via Centre for Reviews and Dissemination – CRD) and LILACS), selecting full HEEs of dengue vaccine. Two independent reviewers screened articles for relevance and extracted the data. The methodology for the quality reporting was assessed using CHEERS checklist. We performed a qualitative narrative synthesis. Results: Thirteen studies conducted in Asian and Latin America countries were reviewed. All studies were favorable to the incorporation of the vaccine. However, the assumptions and values assumed for vaccine efficacy, safety and duration of protection, as well as the choice of the study population and the type of model used in the analyses, associated to an insufficient reporting of the methodological steps, affect the validity of the studies’ results. The quality reporting appraisal showed that the majority (8/13) of the studies reported less than 55% of the CHEERS checklists’ items. Conclusions: This systematic review shows that the economic evaluation of dengue vaccination did not adhere to key recommended general methods for economic evaluation. The presented cost-effectiveness results should not be transferred to other countries. It is recommended to conduct studies with local epidemiological and cost data, as well as assumptions about vaccination that reflect the results observed in clinical trials.     

A Unified Framework for Classification of Methods for Benefit-Risk Assessment

BackgroundPatients, physicians, and other decision makers make implicit but inevitable trade-offs among risks and benefits of treatments. Many methods have been proposed to promote transparent and rigorous benefit-risk analysis (BRA).ObjectiveTo propose a framework for classifying BRA methods on the basis of key factors that matter most for patients by using a common mathematical notation and compare their results using a hypothetical example.MethodsWe classified the available BRA methods into three categories: 1) unweighted metrics, which use only probabilities of benefits and risks; 2) metrics that incorporate preference weights and that account for the impact and duration of benefits and risks; and 3) metrics that incorporate weights based on decision makers’ opinions. We used two hypothetical antiplatelet drugs (a and b) to compare the BRA methods within our proposed framework.ResultsUnweighted metrics include the number needed to treat and the number needed to harm. Metrics that incorporate preference weights include those that use maximum acceptable risk, those that use relative-value–adjusted life-years, and those that use quality-adjusted life-years. Metrics that use decision makers’ weights include the multicriteria decision analysis, the benefit-less-risk analysis, Boers’ 3 by 3 table, the Gail/NCI method, and the transparent uniform risk benefit overview. Most BRA methods can be derived as a special case of a generalized formula in which some are mathematically identical. Numerical comparison of methods highlights potential differences in BRA results and their interpretation.ConclusionsThe proposed framework provides a unified, patient-centered approach to BRA methods classification based on the types of weights that are used across existing methods, a key differentiating feature.     

Methods and applications of genetic analysis in the study of cardiovascular disease: A summary of contributions to GAW8

The analyses of data provided for the cardiovascular disease section of Genetic Analysis Workshop 8 are briefly summarized. Methods using twin, segregation, and linkage analyses are used to determine, characterize, and localize genetic components involved in the etiology of cardiovascular disease and to explore the interaction of these components with known environmental risk factors. © 1993 Wiley-Liss, Inc.     

简议酶分析法

简要介绍了酶分析法及其在部分领域的应用。     

Genetic Analysis Workshop II: further consideration of segregation and linkage analyses in Problem 3

We analyzed disease-marker associations in Problem 3 for the Genetic Analysis Workshop II, using PAP for segregation analysis and LIPED for linkage analysis. In this report we present aspects of our analyses that are not reported in the summary [MacCluer et al, 1984]. Certain features that we added to the running of LIPED to facilitate the analysis are discussed. Furthermore, we tested for Mendelian transmission in the hypothetical trait locus and we calculated modified relative risks for marker-trait genotypes. Some of the problems involved in analyzing complex associations among loci are discussed.     

Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population

Objective:  To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) for the management of multiple sclerosis (MS) compared to best supportive care in the United States.
Methods:  Cost-effectiveness analysis was undertaken using a state transition model of disease natural history and the impact of DMTs for the representative Medicare beneficiary with MS. Costs and outcomes were evaluated from the health-care payer perspective using a 50-year time horizon. Natural history data were drawn from a longitudinal cohort study. The effectiveness of the DMTs was evaluated through a systematic review. Utility data were taken from a study of patients with clinically definite MS in Nova Scotia. Resource use and cost data were derived from the Sonya Slifka database and associated literature.
Results:  When based on placebo-controlled evidence, the marginal cost-effectiveness of interferon beta (IFNβ) and glatiramer acetate compared to best supportive care is expected to be in excess of $100,000 per quality-adjusted life-year gained. When evidence from head-to-head trials is incorporated into the model, the cost-effectiveness of 6 MIU IFNβ-1a is expected to be considerably less favorable. Treatment discontinuation upon progression to Expanded Disability Status Scale 7.0 is expected to improve the cost-effectiveness of all DMTs.
Conclusions:  Further research is required to examine the long-term clinical effectiveness and cost-effectiveness of these therapies. There is no definitive guidance in the United States concerning discontinuation of DMTs; this study suggests that the prudent use of a treatment discontinuation rule may considerably improve the cost-effectiveness of DMTs.